ATE456376T1 - Immortalisierte hepatozyten - Google Patents

Immortalisierte hepatozyten

Info

Publication number
ATE456376T1
ATE456376T1 AT04794437T AT04794437T ATE456376T1 AT E456376 T1 ATE456376 T1 AT E456376T1 AT 04794437 T AT04794437 T AT 04794437T AT 04794437 T AT04794437 T AT 04794437T AT E456376 T1 ATE456376 T1 AT E456376T1
Authority
AT
Austria
Prior art keywords
cell lines
immortalized hepatocytes
immortalized
nontumorigenic
virally
Prior art date
Application number
AT04794437T
Other languages
English (en)
Inventor
Jin Liu
Ronald A Faris
Original Assignee
Multicell Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multicell Technologies Inc filed Critical Multicell Technologies Inc
Application granted granted Critical
Publication of ATE456376T1 publication Critical patent/ATE456376T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
AT04794437T 2003-10-10 2004-10-07 Immortalisierte hepatozyten ATE456376T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51050903P 2003-10-10 2003-10-10
PCT/US2004/033091 WO2006041488A1 (en) 2003-10-10 2004-10-07 Immortalized hepatocytes

Publications (1)

Publication Number Publication Date
ATE456376T1 true ATE456376T1 (de) 2010-02-15

Family

ID=34435100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04794437T ATE456376T1 (de) 2003-10-10 2004-10-07 Immortalisierte hepatozyten

Country Status (9)

Country Link
US (2) US20070104696A1 (de)
EP (2) EP1704227B1 (de)
JP (2) JP2007518426A (de)
AT (1) ATE456376T1 (de)
AU (1) AU2004280238A1 (de)
CA (2) CA2541380A1 (de)
DE (1) DE602004025380D1 (de)
IL (1) IL174787A0 (de)
WO (2) WO2006041488A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239498A1 (en) * 2006-01-12 2010-09-23 Kazuo Ohashi Method of maintaining the function of liver tissue cells over long time
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病ｂ治療剤及びその製造方法
US8099298B2 (en) * 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
WO2009142767A1 (en) * 2008-05-22 2009-11-26 Lentigen Corporation Lentivector-based protein production
BRPI0912175A2 (pt) * 2008-05-28 2015-10-06 Basf Se métodos para diagnosticar indução de enzima do fígado, para determinar se um composto é capaz de induzir indução de enzima do fígado em um indivíduo, e para identificar uma substância para tratar indução de enzima do fígado
CN101967499A (zh) * 2009-12-09 2011-02-09 河南东都生物科技有限公司 一种还原型辅酶q10的生产方法
EP3563859B1 (de) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Von kardiosphären abgeleitete exosomen zur geweberegeneration
EP2951741A2 (de) 2013-02-03 2015-12-09 Genelex Corporation Systeme und verfahren zur quantifizierung und präsentation eines medizinisches risikos aus unbekannten faktoren
CN103981147B (zh) 2013-02-08 2017-11-10 中国科学院上海生命科学研究院 一种新的制备肝实质细胞的方法
JP2015008686A (ja) * 2013-06-28 2015-01-19 三菱レイヨン株式会社 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ
JP6418761B2 (ja) * 2014-03-14 2018-11-07 国立大学法人東京工業大学 肝炎組織体、肝炎ウイルスの感染方法、肝炎組織体の製造方法、肝炎ウイルスの増殖方法、肝炎ワクチンの製造方法、スクリーニング方法、及びキット
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
AU2019216224A1 (en) * 2018-01-30 2020-08-20 Capricor, Inc. Activation-induced tissue-effector cells suitable for cell therapy and extracelluar vesicles derived therefrom
EP3749344A4 (de) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center Verfahren zur therapeutischen verwendung von exosomen und y-rnas
AU2020267561A1 (en) * 2019-05-08 2021-12-23 Capricor, Inc. Therapeutically active cells and exosomes
WO2023084648A1 (ja) * 2021-11-10 2023-05-19 株式会社日立ハイテク 薬剤相互作用解析方法
CN118389446B (zh) * 2024-06-24 2024-10-11 广东乾晖生物科技有限公司 一种无基因插入永生化肝细胞的构建和扩增培养方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584728A (ja) * 1981-05-01 1983-01-11 メデイカル・リサ−チ・インステイチユ−ト・オブ・サンフランシスコ・コ−ポレ−シヨン α−１−抗トリプシンの精製
US5665589A (en) * 1988-12-14 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Human liver epithelial cell lines
US5652097A (en) * 1994-12-14 1997-07-29 Universite De Montreal In vitro test to evaluate the inhibition potency of angiotensin II antagonists on angiotensinogen
US5869243A (en) * 1996-03-05 1999-02-09 Rhode Island Hospital Immortalized hepatocytes
WO1997033996A2 (en) * 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
DE19711266C2 (de) 1997-03-05 1999-06-17 Hepavec Ag Fuer Gentherapie Neue humane Leber-Zellinie
EP1002132A4 (de) * 1997-08-05 2005-04-27 Human Genome Sciences Inc Humane sekretierte proteine
US6653105B2 (en) * 1998-02-11 2003-11-25 Vitagen, Inc. Clonal cells and cell lines derived from C3A cells and methods of making and using them
AU3537099A (en) 1998-04-28 1999-11-16 Masayoshi Nanba Novel immortalized hepatic cell line originating in humans
AU6162199A (en) 1998-09-25 2000-04-17 Harvard-Mit Division Of Health Science And Technology Reversibly immortalized hepatocytes and methods of use
US6517830B1 (en) * 1999-08-05 2003-02-11 Emory University Compositions and methods for the expression of factor VIII polypeptides and uses therefor
EP1295939A4 (de) * 2000-06-15 2005-02-02 Kyowa Hakko Kogyo Kk Insulin-ähnliches wachstumsfaktor bindendes protein
AU2001293074A1 (en) 2000-09-25 2002-04-08 Walter Reed Army Institute Of Research Human liver cell line
CA2447116A1 (en) * 2001-05-17 2002-11-21 Board Of Trustees Of The University Of Illinois Methods for treating liver disease and liver damage with growth hormone and foxm1b

Also Published As

Publication number Publication date
EP1704227B1 (de) 2010-01-27
JP2007518426A (ja) 2007-07-12
AU2004280238A1 (en) 2005-04-21
US7566567B2 (en) 2009-07-28
WO2005034876A2 (en) 2005-04-21
US20070104696A1 (en) 2007-05-10
DE602004025380D1 (de) 2010-03-18
US20070004039A1 (en) 2007-01-04
CA2550452A1 (en) 2006-04-20
AU2004280238A2 (en) 2005-04-21
EP1685252A4 (de) 2006-11-29
IL174787A0 (en) 2006-08-20
EP1704227A1 (de) 2006-09-27
EP1685252A2 (de) 2006-08-02
EP1704227A4 (de) 2007-01-17
CA2541380A1 (en) 2005-04-21
JP2007508019A (ja) 2007-04-05
WO2006041488A1 (en) 2006-04-20
WO2006041488A8 (en) 2006-09-08
WO2005034876A3 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
DE602004025380D1 (de) Immortalisierte hepatozyten
MXPA05000858A (es) Metodo de obtener celulas hepaticas humanas viables, incluyendo celulas hepaticas troncales/progenitoras.
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
TW200716647A (en) Synthesis of (R)-N-methylnaltrexone
GB2442406A (en) Mesoderm and definitive endoderm cell populations
WO2005085422A8 (en) Adult stem cells and uses thereof
NO20074037L (no) Farmasoytiske formuleringer med vedvarende frigivelse
EP1933852A4 (de) Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
CY1112844T1 (el) Ρυθμιστες κυτταρικης προσκολλησης
TW200716646A (en) (S)-N-methylnaltrexone
NO20090305L (no) Cyklosporin formuleringer
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
SG165353A1 (en) Improved human interferon molecules and their uses
MXPA05011522A (es) Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
IL182634A (en) Cytotoxic agents comprising liposomes and a radionucleotide, methods for their preparation, pharmaceutical compositions comprising them, uses and kits thereof
SE0302192D0 (sv) Novel compounds
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
ATE485300T1 (de) Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
ATE459603T1 (de) Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4)
EA200701293A1 (ru) Терапевтическая композиция фактора роста кератиноцитов
ATE549638T1 (de) 13c-mr-bildgebung oder spektroskopie von zelltod
NO20052794L (no) Antibakterielle indolonoksazolidinoner intermediater for fremstilling av disse og farmasoytiske prepareter inneholdende disse
IS2799B (is) Kladribínefnablöndur til inngjafar um munn
TW200602062A (en) Improved formulations of 6-mercaptopurine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties